Company Filing History:
Years Active: 2020
Title: Dequan Dou: Innovator in Cancer Treatment
Introduction
Dequan Dou is a prominent inventor based in Beijing, China. He has made significant contributions to the field of chemical and pharmaceutical technology, particularly in the development of inhibitors for cancer treatment. His innovative work focuses on the STAT3 and ERK signal pathways, which are crucial in cancer cell proliferation and survival.
Latest Patents
Dequan Dou holds a patent for a "STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof." This invention relates to a chemical and pharmaceutical technology that provides a method for inhibiting the phosphorylation of the transcription factor STAT3 and the phosphorylation of ERK. The inhibitor primarily consists of mogrosides and/or their analogs, which have shown effectiveness in inhibiting cancer cell proliferation and promoting apoptosis. The preparation method for these compounds is characterized by its simplicity, strong operability, and high purity of products.
Career Highlights
Dequan Dou is affiliated with the Beijing University of Agriculture, where he continues to advance his research in cancer treatment. His work has the potential to lead to new therapeutic options for patients suffering from various types of cancer.
Collaborations
Some of his notable coworkers include Can Liu and Lanqing Ma, who have contributed to his research endeavors and the development of his patented technologies.
Conclusion
Dequan Dou's innovative work in developing STAT3 and ERK signal pathway inhibitors represents a significant advancement in cancer treatment. His contributions to pharmaceutical technology are paving the way for new therapeutic strategies to combat cancer effectively.